Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.

NCT Number	NCT05945823
Lead Sponsor	Taiho Oncology, Inc.
Conditions	Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
Enrollment	53 participants
Start Date	2023-07-13
Primary Completion	2026-01-28 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-09